Precision BioSciences’ (DTIL) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reaffirmed their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($2.32) EPS, FY2028 earnings at ($1.15) EPS, FY2029 earnings at ($1.40) EPS and FY2030 earnings at $1.09 EPS.

A number of other research firms also recently weighed in on DTIL. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Oppenheimer initiated coverage on Precision BioSciences in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, JonesTrading reaffirmed a “buy” rating and issued a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.25.

Read Our Latest Analysis on DTIL

Precision BioSciences Stock Up 2.6%

Shares of DTIL opened at $7.47 on Monday. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $192.73 million, a PE ratio of -2.04 and a beta of 1.27. The firm’s 50 day moving average is $7.34 and its 200-day moving average is $6.30. Precision BioSciences has a 12 month low of $3.53 and a 12 month high of $9.62.

Precision BioSciences (NASDAQ:DTIL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to analyst estimates of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%. Equities research analysts forecast that Precision BioSciences will post -2.6 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP boosted its holdings in shares of Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after purchasing an additional 318,737 shares in the last quarter. Empery Asset Management LP bought a new position in shares of Precision BioSciences in the 4th quarter valued at $9,130,000. Aberdeen Group plc acquired a new position in shares of Precision BioSciences during the 4th quarter worth $8,897,000. Bleichroeder LP raised its holdings in shares of Precision BioSciences by 54.7% during the 4th quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock worth $6,916,000 after buying an additional 587,500 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its holdings in shares of Precision BioSciences by 497.1% during the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock worth $4,435,000 after buying an additional 887,515 shares in the last quarter. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Precision BioSciences

Here are the key news stories impacting Precision BioSciences this week:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating, maintaining a constructive long-term view of Precision BioSciences despite revising several earnings estimates. HC Wainwright Reiterates Buy Rating for Precision BioSciences
  • Positive Sentiment: The analyst raised its FY2028 EPS forecast to a loss of $1.15 from a loss of $1.91, its FY2029 forecast to a loss of $1.40 from a loss of $2.15, and its FY2030 estimate to positive EPS of $1.09 from $1.08. These revisions suggest improved longer-term expectations and a potential path toward profitability.
  • Neutral Sentiment: Precision BioSciences is scheduled to report earnings on Thursday, making the release a near-term catalyst. Investors will likely focus on cash resources, operating expenses, clinical and partnership progress, and management’s outlook. Precision BioSciences to Post Earnings on Thursday
  • Negative Sentiment: HC Wainwright lowered its quarterly EPS estimates for Q2, Q3, and Q4 2026 to losses of $0.57, $0.58, and $0.59, respectively. Its FY2026 forecast was cut to a loss of $2.07 from $1.29, while the FY2027 forecast fell to a loss of $2.32 from $1.45. The reductions imply greater expected losses and could weigh on sentiment.

Precision BioSciences Company Profile

(Get Free Report)

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

Recommended Stories